儿童慢性非细菌性骨髓炎的临床特征与结局:聚焦唑来膦酸的回顾性队列研究
37%患儿接受ZA,其中77%临床显著改善,80%可评估者影像学显著改善,54%出现轻度短暂流感样症状,无严重不良事件。
要点
- ZA在儿童慢性非细菌性骨髓炎中临床和影像学应答率高且耐受良好。
- ZA每6个月一次输注的方案为其他双膦酸盐提供了实用替代。
- 多数患儿初始使用非甾体抗炎药,ZA用于严重或难治病例。
核心结论
- 唑来膦酸与高临床和影像学应答率相关,且耐受性良好。
主要发现
- 86%为多灶性疾病,63%接受活检,所有患儿初始均使用非甾体抗炎药。
- 10例有ZA前后全身MRI的患儿中,80%显示显著影像学改善。
- 接受ZA者54%报告轻度短暂流感样症状,无严重不良事件。
关键数值与推荐
- ZA平均给药2.6剂,通常每6个月一次输注。
- 3例ZA治疗后需加用TNF抑制剂,2例未用ZA直接接受TNF抑制剂。
临床怎么用
- ZA可用于儿童慢性非细菌性骨髓炎,尤其严重或难治病例,每6个月一次输注方案可行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Chronic non-bacterial osteomyelitis is a rare autoinflammatory bone disease of childhood. Non-steroidal anti-inflammatory drugs are often used first-line, while conventional and biologic disease-modifying antirheumatic drugs and bisphosphonates are reserved for severe or refractory disease. Zoledronic acid (ZA) is used off-label, but robust data on its role remain limited. This study aimed to describe the clinical characteristics, management and outcomes of children with chronic non-bacterial osteomyelitis, with a primary focus on the effectiveness and tolerability of ZA. METHOD: A retrospective review was conducted of children diagnosed with chronic non-bacterial osteomyelitis between 2014 and 2024 at the Royal Children's Hospital, Melbourne. Clinical and magnetic resonance imaging responses to ZA, as well as adverse effects, were evaluated. RESULTS: Fifty-seven patients were included [mean age 10.3 years; 70% female; median follow-up 3.7 years (range 1.4-8.9)]. Multifocal disease was present in 86%, and 63% underwent biopsy. All received non-steroidal anti-inflammatory drugs initially. Twenty-two patients (37%) received zoledronic acid (mean 2.6 doses); 77% showed significant clinical improvement. Three later required tumour necrosis factor inhibitors, and two received tumour necrosis factor inhibitors without prior zoledronic acid. Among 10 patients with pre- and post-zoledronic acid whole-body magnetic resonance imaging, 80% demonstrated significant radiological improvement. Mild, transient flu-like symptoms were reported in 54% of patients treated with zoledronic acid; no serious adverse events occurred. CONCLUSION: Zoledronic acid was associated with high clinical and radiological response rates and was well tolerated. Its infrequent dosing schedule, typically one infusion every six months, offers a practical alternative to other bisphosphonates.
引用
- Herman Y, Akikusa JD, Jones J, et al. Clinical characteristics and outcomes of paediatric chronic non-bacterial osteomyelitis: a retrospective cohort study with focus on zoledronic acid. Rheumatology (Oxford). 2026. PMID: 42615986. doi:10.1093/rheumatology/keag442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。